Breaking Down Chengdu Kanghong Pharmaceutical Group Co., Ltd Financial Health: Key Insights for Investors

Curious whether Chengdu Kanghong Pharmaceutical Group (002773.SZ) is a resilient growth story or a richly priced biotech play? The company posted Q3 revenue of ¥1.17 billion (up 4.75% QoQ) and a TTM revenue of ¥4.67 billion (YoY +6.76%), backed by a 2024 annual revenue of ¥4.45 billion (up 12.51% vs. 2023) and revenue per employee near ¥1.05 million across 4,462 staff; profitability shows momentum with H1 2025 net income of ¥729.7 million and basic EPS of ¥0.79, alongside an impressive gross margin of 89.46%, EBITDA margin 32.82% and operating margin 31.02%, while balance-sheet strength is evident in total assets of ¥9.53 billion versus liabilities of only ¥683.67 million (total equity ¥8.85 billion) and cash & short-term investments of ¥6.00 billion-liquidity ratios of current 10.36 and quick 9.69 reinforce that position; market valuation and multiples merit scrutiny too: market cap ¥27.59 billion, TTM P/E 22.01 (forward P/E 20.80), P/S 5.91, P/B 3.02, EV ¥21.19 billion with EV/EBITDA 13.56 and EV/FCF 15.76-balanced by risk vectors (regulatory hurdles, competitive pressure, FX and supply-chain exposure) and upside avenues (international expansion, R&D, partnerships and pipeline development) that make a closer read of the detailed metrics essential for investors.

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Revenue Analysis

Chengdu Kanghong Pharmaceutical Group reported steady top-line expansion driven by core product sales and international penetration. Key headline figures for recent periods and structural metrics are summarized below.

• Quarter ending 2025-09-30 revenue: 1.17 billion CNY (QoQ +4.75%).
• Trailing twelve months (TTM) revenue: 4.67 billion CNY (YoY +6.76%).
• Full-year 2024 revenue: 4.45 billion CNY (2024 vs 2023: +12.51%).
• Revenue per employee: ~1.05 million CNY across 4,462 employees.
• Market capitalization: 27.59 billion CNY; Price-to-Sales (P/S): 5.91.

Revenue growth trend: the company demonstrates a consistent upward trajectory across quarterly and annual frames, with FY2024 posting double-digit year-on-year growth and the latest quarter showing sequential improvement. Operational scale (revenue per employee) and valuation (P/S ~5.91) provide context for margin leverage and investor expectations.

Further background on the company's history, ownership and business model can be found here: Chengdu Kanghong Pharmaceutical Group Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Profitability Metrics

• Net income (H1 2025): 729.70 million CNY (H1 2024: 692.22 million CNY)
• Basic EPS (H1 2025): 0.79 CNY (H1 2024: 0.75 CNY)
• Gross profit margin (2024): 89.46% - YoY growth: 13.20%
• EBITDA margin: 32.82% - YoY growth: 10.58%
• Operating margin: 31.02% - YoY growth: 9.54%
• Net profit margin (H1 2025): 26.27% - down 0.98 percentage points from 27.25% in prior period

• Strong gross margin (89.46% in 2024) underpins core product profitability and leverages high-margin pharmaceutical sales.
• EBITDA and operating margin expansion (32.82% and 31.02%) indicate improved operating efficiency and cost control year-over-year.
• Net income and EPS growth in H1 2025 show continued earnings momentum despite a modest decline in net margin versus prior period.
• Monitor potential drivers of the slight net margin contraction (H1 2025) such as non-operating items, tax effects, or one-time costs.

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Debt vs. Equity Structure

• Total assets (June 2025): 9.53 billion CNY
• Total liabilities (June 2025): 683.67 million CNY
• Total equity (June 2025): 8.85 billion CNY
• Debt-to-equity ratio: 0.00
• Current ratio: 10.36
• Quick ratio: 9.69
• Interest coverage ratio: N/A (no debt)

• Equity-dominant balance sheet: equity represents ~92.9% of total assets (8.85 / 9.53).
• Liabilities are modest: liabilities represent ~7.2% of total assets (0.684 / 9.53).
• Extremely conservative leverage profile with virtually no financial debt exposure.
• High liquidity ratios imply capacity to cover short-term obligations many times over without drawing on financing.

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Liquidity and Solvency

Key liquidity and solvency indicators for Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) show solid cash reserves, improving operating cash generation, and healthy profitability ratios that support balance-sheet strength.

• Cash and short-term investments: 6.00 billion CNY (+17.17% year-over-year)
• Net change in cash (H1 2025): -84.24 million CNY (down 31.83% year-over-year)
• Free cash flow: 365.49 million CNY (+14.34% year-over-year)
• Operating cash flow: 482.71 million CNY (+20.95% year-over-year)
• Return on assets (ROA): 8.68%
• Return on equity (ROE): 14.03%

Interpretation highlights:

• Strong liquidity buffer with 6.00 billion CNY in cash and equivalents supports near-term obligations and R&D/investment flexibility.
• Operating cash flow growth (+20.95%) and rising free cash flow (+14.34%) indicate improving cash conversion from core operations despite a negative net change in cash in H1 2025.
• ROA of 8.68% and ROE of 14.03% suggest efficient asset use and solid returns for equity holders, bolstering solvency metrics.
• Monitor the H1 2025 negative net change in cash (-84.24M CNY), which could reflect timing of investing/financing activities rather than operating weakness given OCF and FCF trends.

Further investor details: Exploring Chengdu Kanghong Pharmaceutical Group Co., Ltd Investor Profile: Who's Buying and Why?

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Valuation Analysis

• TTM P/E: 22.01 - the market is paying 22.01 times the last 12 months' reported earnings.
• Forward P/E: 20.80 - expected earnings reduce the multiple modestly versus TTM.
• P/B: 3.02 - shares trade at roughly three times book value, indicating a premium to net assets.
• P/S: 5.91 - the market values each yuan of revenue at ~5.91 CNY.
• EV: 21.19 billion CNY - total enterprise valuation.
• EV/EBITDA: 13.56 - valuation relative to operating profitability.
• EV/FCF: 15.76 - valuation relative to free cash flow generation.
• PEG: Not available - growth-adjusted P/E insights limited by lack of reliable growth estimate.

• Relative context: P/E ~22 and EV/EBITDA ~13.6 place the company in a mid-to-high valuation band compared to generic manufacturing peers but may be consistent with specialty pharma peers that command premiums for pipeline, IP, or recurring margins.
• Cash-flow lens: EV/FCF of 15.76 signals investors pay a material premium for free cash flow; verify recent FCF trends and one-off items when modeling intrinsic value.
• Balance-sheet lens: P/B of 3.02 suggests intangible value (R&D, patents, goodwill) or expected ROE above accounting book returns.

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Risk Factors

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) operates in a high-stakes, highly regulated industry. Below are the primary risk vectors investors should monitor, paired where possible with quantitative indicators and scenario implications.

• Regulatory approval and pipeline risk: Clinical trial outcomes and regulatory timelines in China, the EU and other jurisdictions can materially affect revenue timing. Recent regulatory scrutiny across the pharmaceutical sector has extended approval windows by an average of 6-12 months in high-complexity submissions, which can delay peak sales for late-stage assets.
• Currency and FX exposure: International sales and imported API/raw material purchases expose Kanghong to RMB exchange-rate moves. A 5% depreciation of RMB vs. USD/EUR can increase COGS for imported inputs by an equivalent magnitude, tightening gross margins.
• Competitive pressure: Intense competition in ophthalmology and CNS therapeutics may force price concessions. If pricing pressure compresses realized prices by 5-10%, EBITDA margins could decline materially versus historical levels.
• Supply chain and raw material risk: Disruptions (logistics, supplier outages, regulatory holds) can drive API lead-time increases and one-off expense shocks. Historical sector-wide API shortages have pushed input costs up 10-30% during constrained periods.
• Healthcare policy and reimbursement shifts: Changes in national procurement, NRDL adjustments, or payer formulary decisions can rapidly re-weight demand for specific brands. Inclusion/exclusion decisions can change market share by double-digit percentage points within 12 months.
• Product liability and litigation: Adverse safety events or post-market findings may result in recalls, legal settlements, and reputational damage. Large-scale product liability outcomes in pharma can exceed hundreds of millions RMB depending on litigation scope.

• Scenario sensitivity - FX: A sustained 10% RMB depreciation vs. USD could raise total COGS by ~3-6% (depending on import intensity), reducing gross margin by ~100-300 bps.
• Scenario sensitivity - Pricing: A 7% realized price erosion across core portfolio could reduce operating profit by roughly 4-6 percentage points, given current cost structure.
• Scenario sensitivity - Supply shock: A temporary 20% increase in API costs for one quarter could shave ~1-2% off annual net profit if not passed to customers.

Key operational and compliance monitoring points for investors:

• Pipeline milestones and regulatory filings timeline (domestic NMPA and any international EMA/FDA interactions).
• Quarterly R&D burn rate and capitalized R&D vs. expensed R&D trends.
• Gross margin trend and input-cost inflation disclosures.
• Reimbursement/NRDL negotiation outcomes and tender participation results.
• Supply chain disclosures, material supplier concentration and alternative sourcing strategies.
• Contingent liabilities and litigation reserves reported in annual/quarterly filings.

For more on the company's stated direction and strategic priorities, see: Mission Statement, Vision, & Core Values (2026) of Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Growth Opportunities

• International market expansion - leveraging regulatory approvals and export channels to address large unmet needs outside China, particularly in ophthalmology and specialty biologics.
• R&D investment - continued allocation toward clinical development and biologics can translate into differentiated, higher-margin products.
• Partnerships & M&A - licensing deals, co-development agreements, and bolt-on acquisitions to fill capability gaps (manufacturing, regulatory, late-stage assets) can speed time-to-market.
• Therapeutic diversification - moving beyond core ophthalmology into retina-adjacent or systemic specialty areas reduces single-product exposure.
• Digital health integration - remote monitoring, real-world evidence, and tele-ophthalmology can improve patient retention and adherence, and optimize commercial reach.
• Pipeline strengthening - advancing pivotal trials and securing additional indications for lead assets drives medium- to long-term revenue upside.

• Global ophthalmology therapeutics market: estimated in the high tens of billions USD (market forecasts commonly project ~$30-40+ billion range within the next 3-5 years), underscoring large addressable markets for retina therapies.
• Biologics and specialty drugs typically command premium pricing and margins versus small molecules; successful international commercialization can materially boost top-line and EBITDA margins.
• R&D intensity in innovative Chinese biopharma commonly ranges from mid-to-high single-digit up to low double-digit percentages of revenue; increasing this allocation signals commitment to pipeline depth.

• Regulatory filings/approvals outside China (MAA/NDA/EMA/US IND/NDA progress).
• Key Phase II/III readouts and clinical milestone achievements for leading assets.
• New licensing/co-development agreements or cross-border M&A announcements.
• Annual R&D spend and hiring in clinical, regulatory, and international commercial functions.
• Partnerships with digital health platforms, or pilot programs demonstrating improved patient engagement or real-world outcomes.